Oxford Cancer Analytics

About

Oxford Cancer Analytics (OXcan) is a medtech company founded in 2020, focused on early cancer detection through liquid biopsy blood tests. The company utilizes advanced proteomics and AI-driven machine learning to enhance the accuracy of cancer diagnostics. Headquartered in the Bioescalator Innovation Building in Oxford, England, OXcan has a multidisciplinary team of about 15 members across the U.K., U.S., and Canada. The company's mission is to transform early cancer detection and management, particularly for lung cancer, which is the leading cause of cancer deaths globally. OXcan's patented platform identifies key biomarker signatures from thousands of proteins, significantly improving detection rates for multiple cancer types. They maintain a state-of-the-art proteomics lab dedicated to advancing liquid biopsy technologies. In January 2025, OXcan raised US$11 million in Series A funding to support the deployment of their tests and expand their team. The company collaborates with leading lung cancer screening programs and partners with organizations like Prior Labs to enhance their AI applications in lung disease diagnostics.